NewcelX AG (NCEL) Financier

NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.